Patents by Inventor Larisa J. Geskin

Larisa J. Geskin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
    Patent number: 11598778
    Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: March 7, 2023
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa J. Geskin, Brittany Lynn O'Neill Dulmage, Louis D. Falo, Jr.
  • METHOD FOR DIAGNOSIS, PROGNOSIS AND DETERMINATION OF TREATMENT FOR CUTANEOUS T-CELL LYMPHOMA
    Publication number: 20210311062
    Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
    Type: Application
    Filed: June 18, 2021
    Publication date: October 7, 2021
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa J. Geskin, Brittany Lynn O'Neill Dulmage, Louis D. Falo, JR.
  • Method for diagnosis, prognosis and determination of treatment for cutaneous t-cell lymphoma
    Patent number: 11067577
    Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 20, 2021
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa J. Geskin, Brittany Lynn O'Neill Dulmage, Louis D. Falo, Jr.
  • METHOD FOR DIAGNOSIS, PROGNOSIS AND DETERMINATION OF TREATMENT FOR CUTANEOUS T-CELL LYMPHOMA
    Publication number: 20200033348
    Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 30, 2020
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa J. Geskin, Brittany Lynn O'Neill Dulmage, Louis D. Falo, JR.
  • Method for diagnosis, prognosis and determination of treatment for cutaneous T-cell lymphoma
    Patent number: 10473661
    Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: November 12, 2019
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa J. Geskin, Brittany Lynn O'Neil Dulmage, Louis D. Falo, Jr.
  • METHODS FOR DIAGNOSIS OF CUTANEOUS T-CELL LYMPHOMA
    Publication number: 20160169901
    Abstract: The present invention is based, at least in part, on the discovery of biomarkers identified herein which are associated with cutaneous T-cell lymphoma (CTCL). Accordingly, the present invention provides methods for diagnosing CTCL, e.g., early stage CTCL, including mycosis fungoides (MF) and Sézary syndrome (SS), and to distinguish CTCL from other skin disorders.
    Type: Application
    Filed: December 10, 2015
    Publication date: June 16, 2016
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Larisa J. GESKIN, Oleg E. AKILOV
  • METHOD FOR DIAGNOSIS, PROGNOSIS AND DETERMINATION OF TREATMENT FOR CUTANEOUS T-CELL LYMPHOMA
    Publication number: 20150344971
    Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
    Type: Application
    Filed: August 6, 2015
    Publication date: December 3, 2015
    Applicant: UNIVERSITY OF PITTSBURGH -OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa J. Geskin, Brittany Lynn O'Neil Dulmage, Louis D. Falo, JR.